revealed 20% LM, 60% LAD, 50% CX, 60% RCA, and EF of 72%, with a regurgitant fraction of 33%.
Prior echo showed moderate to severe MR, EF 60-70%, and elevated PA pressures.
remote renal calculus HTN MR  Social History: electrical contractor, lives with wife quit smoking 35 years ago ( was smoking up to 3 ppd);  has one drink per day  Family History: non-contributory  Physical Exam: HR 74 RR 18   114/60 5'[**75**]" 192 #  Pertinent Results: [**2170-11-30**] 06:43AM BLOOD WBC-13.5* RBC-5.17 Hgb-17.1 Hct-50.1 MCV-97 MCH-33.0* MCHC-34.1 RDW-13.7 Plt Ct-229 [**2170-12-9**] 05:05AM BLOOD WBC-15.3* RBC-3.41* Hgb-11.0* Hct-33.0* MCV-97 MCH-32.3* MCHC-33.3 RDW-15.1 Plt Ct-390 [**2170-12-9**] 05:05AM BLOOD PT-19.2* INR(PT)-2.6 [**2170-12-9**] 05:05AM BLOOD Plt Ct-390 [**2170-11-30**] 06:43AM BLOOD PT-14.1* PTT-23.7 INR(PT)-1.4 [**2170-12-8**] 05:20AM BLOOD Glucose-89 UreaN-22* Creat-1.0 Na-138 K-3.6 Cl-95* HCO3-33* AnGap-14 [**2170-11-30**] 01:30PM BLOOD UreaN-18 Creat-0.9 Cl-108 HCO3-23 [**2170-12-6**] 12:10PM BLOOD ALT-55* AST-30 LD(LDH)-422* AlkPhos-82 Amylase-279* TotBili-1.5 [**2170-12-6**] 12:10PM BLOOD Lipase-88* [**2170-12-6**] 12:10PM BLOOD Albumin-3.2*  Brief Hospital Course: Admitted [**11-30**] and had MVR/CABG x1 /Maze and ligation of [**Name Prefix (Prefixes) **] [**Last Name (Prefixes) 1916**].Transferred to CSRU in stable condition on titrated neo and propofol drips.
Echo postop showed no tamponade and EF intact per report.
On POD #6, his INR bumped to 7.0, and then 7.5.
He had some arm heaviness at that time, so neuro consult was done (negative), including CT scan ( also negative).
Repeat INR later that day was 2.3.
UA sent and CXR done for elevated WBC.
INR on day of discharge 3.4 Blood draw on [**12-11**] (Tues, [**Last Name (un) **], Sat draws) with VNA, and coumadin dosing with Dr. [**Last Name (STitle) 98715**] [**Name (STitle) **] as done pre-op.
Warfarin 1 mg Tablet Sig: One (1) Tablet PO at bedtime for 1 days: Take as directed by Dr. [**First Name8 (NamePattern2) **] [**Name (STitle) **]  INR goal 2-2.5.
